Septerna, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Septerna, Inc. (SEPN) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $425.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-10
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $3.96M, a 81.14% increase year-over-year.
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.53M.
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $4.34M, a 45.36% increase year-over-year.
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $1.28M, a 795.80% increase year-over-year.
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $4.36M, a 22.31% increase from fiscal 2024.
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $3.56M, a 44.23% increase from fiscal 2023.
- Septerna, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $2.47M.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $425.00K 10-Q · filed 2026-08-10 | $4.76M derived: sum of 3 quarters · filed 2026-08-10 | $6.04M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$3.53M 10-Q · filed 2026-05-11 | $806.00K derived: sum of 2 quarters · filed 2026-05-11 | $2.09M derived: sum of 3 quarters · filed 2026-05-11 | $4.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.62M derived: sum of 2 quarters · filed 2026-03-09 | $7.80M derived: sum of 3 quarters · filed 2026-08-10 | $4.36M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.47M derived: sum of 2 quarters · filed 2026-08-10 | $20.00K 10-Q · filed 2025-11-10 | $3.00M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$1.26M 10-Q · filed 2026-08-10 | $1.72M derived: sum of 3 quarters · filed 2026-08-10 | $1.87M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$3.45M 10-Q · filed 2026-05-11 | -$461.00K derived: sum of 2 quarters · filed 2026-05-11 | -$318.00K derived: sum of 3 quarters · filed 2026-05-11 | $1.74M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.13M derived: sum of 2 quarters · filed 2026-03-09 | $5.18M derived: sum of 3 quarters · filed 2026-03-09 | $3.56M 10-K · filed 2026-03-09 |
| 2024-09-30 | $143.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.20M derived: sum of 2 quarters · filed 2025-11-10 | $579.00K 10-Q · filed 2025-11-10 | $2.49M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $436.00K 10-Q · filed 2025-08-11 | $2.35M derived: sum of 3 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$1.62M 10-Q · filed 2025-05-15 | $295.00K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.47M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $559.00K 10-Q · filed 2024-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |